V ascular endothelial growth factor/vascular permeability factor was first discovered as a tumor-secreted factor that increases vascular permeability. 1 Subsequently, VEGF/VPF was shown to promote endothelial cell proliferation and migration. [2] [3] [4] [5] The latter features have led to extensive investigation of the role of VEGF/VPF in pathological 3, 6, 7 and therapeutic 8 -12 angiogenesis. Despite a body of evidence indicating that angiogenesis is preceded and/or accompanied by enhanced VP, 13 this feature of VEGF/VPF has received considerably less attention. In particular, the mechanisms that account for VEGF/VPF-induced VP have remained enigmatic. Moreover, the extent to which an increase in VP may be a shared feature of angiogenic growth factors in general has not been clarified.
Accordingly, we used an in vivo assay described originally by Miles and Miles 14 to study the putative mediators of VP induced by VEGF/VPF. This in vivo assay, which has been used previously to document the permeability feature of VEGF/VPF, 1, [15] [16] [17] [18] involves intravenous injection of a vital dye followed by intradermal administration of candidate VPpromoting agents. Increased VP is recognized by discrete extravasation of dye into the intradermal bleb.
Previous studies have implicated NO in the regulation of VP, 19 -22 and in vitro 23, 24 work has indicated that VEGF/VPF stimulates production of NO in macrovascular endothelium. More recently, prostaglandins have been suggested to contribute to the regulation of VP and angiogenesis. 25, 26 Indeed, we demonstrate here that VP induced by VEGF/VPF in vivo results from the synergistic action of both NO and prostacyclin and that this property appears unique to VEGF/VPF among angiogenic cytokines.
Methods

Animals
All protocols were approved by the Institutional Animal Care and Use Committee of St Elizabeth's Medical Center, Tufts University School of Medicine.
Miles Assay
We used male hairless albino guinea pigs (weight, 200 to 600 g, nϭ30) (Charles River Laboratories). These guinea pigs are euthymic and immunocompetent. Animals were lightly anesthetized with ether (Fisher Scientific). A solution of EBD (Sigma) (0.5% in saline) was filtered through a 0.2-m micropore filter (Corning) before use. The animals were then given 0.5 to 1.0 mL of 0.5% EBD through the left femoral vein. EBD binds to circulating plasma proteins and extravasates in response to certain reagents (vide infra), rendering hyperpermeable dermal sites blue.
14 After the animals regained consciousness, various reagents were injected intradermally in volume of 0.1 mL. Intradermal injections were made into the trunk posterior to the shoulder 20 minutes after intravenous injection of EBD with a 30-gauge needle (Becton Dickinson), causing a bleb 9 to 11 mm in diameter. Increase in VP was assessed by the leakage of blue dye into the bleb.
14 As originally described by Miles and Miles, 14 a small area of traumatic blueing 1 to 3 mm in diameter may be seen at the center of the bleb after intradermal injection of saline control. Two persons assessed intensity and area of the blue color changes within blebs.
Protocol 1: Effects of VEGF/VPF on VP
At 20 minutes after EBD injection, the following were injected intradermally: (a) saline alone (as vehicle control); (b) VEGF/VPF (8, 16, 32, 64 , and 128 ng); and as positive controls, (c) PAF (0.01, 0.1, 1, 10, and 100 mol/L) (d) histamine (1, 10, 100, and 1000, nmol/L), and (e) bradykinin (1, 10, 100, and 1000 nmol/L). At 15 minutes, dermal blueing was assessed.
Protocol 2: Effect of PAF Receptor Antagonist and Histamine H1 Receptor Antagonist on VEGF/VPF-Induced VP
PAF is a potent endogenous stimulator of VP with an unknown mechanism of action. Guinea pigs received the PAF antagonist CV-6209 (Biomol) (2 mg/kg) 27 10 minutes before EBD injection. To confirm the blocking effect of CV-6209, we also examined PAFmediated (0.1, 1, and 10 mol/L) VP after administration of CV-6209.
The effects of histamine H1 receptor antagonist diphenhydramine (10 mg/kg) on VEGF/VPF-induced VP was investigated by administration of diphenhydramine (10 mg/kg) 10 minutes before administration of EBD. The blocking effect of diphenhydramine was examined with histamine (1, 10, 100, and 1000 nmol/L) after administration of diphenhydramine.
Protocol 3: Effects of Other Angiogenic Cytokines on VP
At 20 minutes after EBD injection, the following were injected intradermally: (a) bFGF (8 to 128 ng), (b) aFGF (8 to 128 ng), (c) GM-CSF (8 to 128 ng), (d) scatter factor/HGF (8 to 128 ng), (e) PDGF-BB (8 to 128 ng), (f) TGF-␤ (8 to 128 ng), and (g) PlGF (8 to 128 ng). PAF was the positive control, saline the negative control.
Protocol 4: Role of Receptor Tyrosine Kinase in VEGF/VPF-Induced VP
The receptor tyrosine kinases Flk-1/KDR/VEGF-R2 and Flt-1/ VEGF-R1 bind VEGF/VPF with high affinity. 28 -31 Accordingly, we tested the effect of the tyrosine kinase inhibitors genistein and herbimycin A on VEGF/VPF-stimulated VP. Ten minutes after administration of EBD, saline (control), genistein (100 mol/L), or herbimycin A (1 mol/L) was intradermally injected as 0.15 mL volume. Ten minutes later (ie, 20 minutes after EBD), the maximum dose of VEGF/VPF used here to stimulate permeability (128 ng) was injected in 0.1 mL volume into the identical dermal area.
Although VEGF/VPF binds to both Flt-1/VEGF-R1 and Flk-1/ KDR/VEGF-R2 receptor tyrosine kinases, PlGF has been shown to bind principally to Flt-1/VEGF-R1. [32] [33] [34] To further determine which receptor tyrosine kinase is responsible for VEGF/VPF-induced VP, we tested PlGF (R&D Systems) (8 to 128 ng) on VP as well. Two NO synthase inhibitors, L-NNA (10 mg/kg) or L-NAME (20 mg/kg) were used to investigate the role of NO on VEGF/VPFinduced VP. These were injected through the penile or femoral vein immediately before administration of EBD. Twenty minutes later, (a) saline alone (negative control), (b) VEGF/VPF (8, 16, 32 , and 64 ng), or (c) PAF (0.01, 0.1, 1, 10, and 100 mol/L) was injected intradermally and VP assessed.
To exclude a nonspecific action of L-NAME, the effect of the inactive enantiomer D-NAME (20 mg/kg) on VEGF/VPF-induced VP was also tested. D-NAME was injected through the penile vein before administration of EBD. At 20 minutes after EBD, (a) saline alone or (b) VEGF/VPF (8, 16, 32, 64 , and 128 ng) was injected intradermally.
To assess whether NO donors can mimic VEGF/VPF-induced VP, we administered NO donors, SNP (10, 50, 100, and 500 mol/L) or S-nitroso-N-acetyl penicillamine (SNAP) (10, 100, and 500 mol/L in 0.1 mL solution). At 20 minutes after EBD administration, (a) saline alone, (b) SNP or SNAP, or (c) PAF was injected intradermally.
Protocol 6: Role of Prostaglandin(s) in VEGF/VPF-Induced VP
To examine a role for prostaglandins in VEGF/VPF-induced VP, indomethacin (5 mg/kg), a cyclooxygenase inhibitor, was injected intraperitoneally, 26 before EBD administration. At 20 minutes after EBD injection, (a) saline, (b) VEGF/VPF (8, 16, 32 , and 64 ng), or (c) PAF was injected intradermally.
To assess whether prostacyclin, a major metabolite of arachidonic acid, can mimic VEGF/VPF-induced VP, we investigated the direct effect of intradermal injection of prostacyclin or its stable analog taprostene. 35 At 20 minutes after EBD, (a) saline, (b) prostacyclin or taprostene (0.01, 0.1, 1, and 10 mol/L), or (c) PAF was injected intradermally.
Finally, SNP and taprostene were mixed together and injected intradermally to assess the combined activity of NO and prostacyclin in enhancing VP.
Protocol 7: Effect of NO-Independent Vasoconstriction on VP
To exclude the possibility that inhibition of VEGF/VPF-induced VP by L-NAME was simply the result of L-NAME-induced vasoconstriction, we examined the effects of phenylephrine on VEGF/VPFinduced VP. Phenylephrine was administered intravenously to achieve a comparable increase in systemic blood pressure (BP) to that resulting from L-NAME (20 mg/kg). After administration of sodium pentobarbital (60 mg/kg IP), a 22-gauge cannula was inserted into the left common carotid artery for BP monitoring. After similar increases in Selected Abbreviations and Acronyms aFGF, bFGF ϭ acidic, basic fibroblast growth factor BMEC ϭ bovine microvascular endothelial cells EBD ϭ Evans blue dye GM-CSF ϭ granulocyte macrophage-colony stimulating factor HGF ϭ hepatocyte growth factor
-nitro-L-arginine NO ϭ nitric oxide PAF ϭ platelet-activating factor PDGF-BB ϭ platelet-derived growth factor-BB PlGF ϭ placenta growth factor SNP ϭ sodium nitroprusside TGF-␤ ϭ transforming growth factor-␤ VEGF ϭ vascular endothelial growth factor VP ϭ vascular permeability VPF ϭ vascular permeability factor BP were recorded in response to either L-NAME or phenylephrine, EBD was administered to evaluate VEGF/VPF-induced VP.
Protocol 8: Effect of Locally Administered L-NAME or Phenylephrine on VEGF/VPF-Induced VP
To analyze the effects of L-NAME and phenylephrine administered locally rather than systemically on VP, VEGF/VPF was dissolved (8 to 128 ng in 0.1 mL) in saline containing either L-NAME (1 mmol/L) or phenylephrine (1 mol/L). We also examined the impact of either L-NAME (0.001 to 1 mmol/L) or phenylephrine (0.01 to 10 mol/L) administered alone.
Bovine Microvascular Endothelial Cell Culture
Because modulation of VP involves the microcirculation, we used BMEC (American Type Culture Collection) to study the effect of VEGF/VPF on stimulating release of NO and prostacyclin in vitro. BMEC express mRNA and protein for both constitutive endothelial NO synthase and prostaglandin H synthase-1 and thus may secrete NO and prostaglandins. 36 Cells were grown at 37°C in a humidified atmosphere of 5% CO 2 ϩ95% air in phenol red-free MEM containing 20% FBS, 0.6 mmol/L L-arginine, ampicillin, and kanamycin. Cells were plated at confluence at 10 6 cells/mL (1 mL per well). After attachment to plates, medium was replaced by 1 mL of sterile Krebs/Henseleit (K-H) buffer.
Measurement of Nitrite Production in BMEC
After release, NO reacts with O 2 to yield stable nitrite metabolite. Nitrite concentrations were measured by the Griess reaction to estimate total amounts of NO released from the BMEC. At different time points after addition of VEGF/VPF, 300 L of K-H buffer was removed and mixed with 30 L of Griess reagent (1% sulfanilic acid, 0.1% naphthalene-ethylene diamine in 5% phosphoric acid; Sigma), incubated for 10 minutes at room temperature, and absorbance measured at 548 nm. For a blank, 300 L of fresh K-H buffer was mixed with 30 L of Griess reagent. Concentrations were determined by comparison with sodium nitrite standard. Lower limit of detection was 0.1 mol/L of nitrite.
Measurement of VEGF/VPF-Induced Prostacyclin Production in BMEC
The stable metabolite of prostacyclin, 6-keto PGF1␣ in K-H buffer conditioned by BMEC treated with or without VEGF/VPF, was measured by enzyme immunoassay kit (Amersham) at serial time points in response to VEGF/VPF. The lower limit of detection was 6 pg/mL.
Histological Examination After Intradermal Injection of VEGF/VPF
Five-micron-thick sections of skin were cut, stained with hematoxylin-eosin and/or Giemsa, and examined by light microscopy after intradermal injection of VEGF/VPF (128 ng in 0.1 mL bleb). Control histology was obtained from the skin injected with saline (0.1 mL).
Reagents
Reagents were all purchased from Sigma Chemical unless otherwise specified. Tissue culture reagents were all purchased from Life Technologies unless otherwise specified. Recombinant human VEGF/VPF, purified from Escherichia coli, was the generous gift of Drs N. Ferrara, B. Keyt, and S. Bunting at Genentech. Taprostene was the generous gift of Drs J. Schneider and E. Friderichs in Grünenthal. Scatter factor (HGF) was the generous gift of Dr R. Schwall at Genentech. GM-CSF was the generous gift of Dr T.L. Nagabhushan at Schering-Plow.
Data Analysis
All data are expressed as meanϮSEM (nϭnumber of cell culture wells). Comparison of means between two groups was performed by unpaired Student's t test. If more than two groups were compared, one-way ANOVA was used to evaluate significant differences among these groups; if significant differences were obtained, each difference was further examined by Fisher's t test. Probability was considered to be statistically significant at PϽ.05.
Results
Analysis of VP for Angiogenic Cytokines and Putative Mediators
VEGF/VPF Increases VP
Repeated intradermal injection of the vehicle control saline (0.1 mL) did not increase VP. In contrast, intradermal injection of VEGF/VPF (8, 16, 32, 64 , and 128 ng) significantly increased VP in a dose-dependent manner (Fig 1A) . VEGF/ VPF started to render injected area blue at 149Ϯ5 seconds (nϭ5) after intradermal injection. As positive controls, we used PAF (0.01, 0.1, 1, 10, and 100 mol/L), bradykinin (1, 10, 100, and 1000 nmol/L), and histamine (1, 10, 100 ,and 1000 nmol/L), all of which increased VP (Fig 1, B, C, and D) .
Effects of PAF Receptor Antagonist and Histamine H1 Receptor Antagonist on VEGF/VPF-Mediated Increase in VP
Because PAF and histamine are well-known endogenous mediators of VP, we tested the effect of PAF receptor antagonist CV-6209 and histamine H1 receptor antagonist diphenhydramine on VEGF/VPF-mediated VP. CV-6209 (2 mg/kg) and diphenhydramine (10 mg/kg) inhibited PAFmediated (0.1, 1, and 10 mol/L) and histamine-mediated (1, 10, 100, and 1000 nmol/L) VP, respectively. However, both CV-6209 and diphenhydramine failed to inhibit VEGF/VPFinduced VP (Fig 1, E and F) . Thus PAF and histamine do not mediate VEGF/VPF-induced VP.
Other Angiogenic Cytokines Do Not Increase VP
Because increased VP has been considered to be associated with in vivo angiogenesis, 13 we investigated the effects of bFGF (8, 16, 32, 64 , and 128 ng), aFGF (8, 16, 32, 64 , and 128 ng), GM-CSF (8, 16, 32, 64 , and 128 ng), scatter factor (8, 16, 32, 64 , and 128 ng), PDGF-BB (8, 16, 32, 64 , and 128 ng), and TGF-␤ (8, 16, 32, 64 , and 128 ng) on VP. None enhanced VP (Fig 2, A through F) , consistent with previous reports. We first assessed the role of functional receptor tyrosine kinase in VEGF/VPF-induced VP by using the tyrosine kinase inhibitors genistein (100 mol/L) and herbimycin A (1 mol/L) followed by an intradermal injection of VEGF/ VPF (128 ng). Genistein or herbimycin A alone did not change VP (Fig 3) . When VEGF/VPF was injected into an untreated skin area, VEGF/VPF increased VP as before. When VEGF/ VPF was injected at the area previously treated with genistein or herbimycin A, however, VP was attenuated (Fig 3) . These results document that tyrosine phosphorylation is required for VEGF/VPF-mediated VP.
We then tested the effects of PlGF on VP. PlGF binds to only Flt-1/VEGF-R1 but not to Flk-1/KDR/VEGF-R2
receptor tyrosine kinase. 32, 37 PlGF (8, 16, 32, 64, and 128 ng) did not increase VP (Fig 3) , suggesting that Flk-1/KDR/ VEGF-R2 is the relevant receptor tyrosine kinase for VEGF/ VPF-induced VP.
Effects of the NO Synthase Inhibitors on VEGF/VPF-Induced VP
We next examined the role of NO in VEGF/VPF-mediated VP by using the NO synthase inhibitors L-NNA (10 mg/kg) or L-NAME (20 mg/kg). Both attenuated VEGF/VPF-induced VP. The inhibitory effect of L-NAME on VEGF/VPFinduced VP is shown in Fig 4B. In contrast, pretreatment with NO synthase inhibitors did not alter VP induced by PAF (Fig  4B) , indicating that PAF does not induce VP through NO. The inactive stereoisomer D-NAME (20 mg/kg), which does not inhibit endothelial NO synthesis, failed to inhibit VEGF/ VPF-induced VP (Fig 4C) . VEGF/VPF-mediated increase in VP was thus dependent on local NO production.
Effects of the Cyclooxygenase Inhibitor Indomethacin on VEGF/VPF-Induced VP
Pretreatment with indomethacin (5 mg/kg) inhibited VP stimulated by VEGF/VPF (Fig 4D) . In contrast, indomethacin pretreatment had no effect on PAF-induced VP. Histological examination disclosed no evidence of VEGF/VPF-associated inflammatory cell infiltrate and/or mast cell degranulation at the site of intradermal injection with or without indomethacin pretreatment. Thus VP due to VEGF/VPF, in contrast to PAF, was also dependent on local prostaglandin(s).
Effect of NO-Independent Vasoconstriction on VEGF/VPF-Induced Increase in VP
In vivo injection of L-NAME (20 mg/kg) increased systemic BP from 96/70 to 132/96 mm{ths}Hg and inhibited VEGF/VPFinduced VP (Fig 5A) . Phenylephrine (0.05 to 0.2 mg/kg) was injected in a cumulative fashion, and 0.2 mg/kg of phenylephrine increased BP from 91/69 (baseline) to 140/92 mm Hg, similar to the increase in BP recorded after administration of L-NAME. In contrast to L-NAME, however, phenylephrine did not inhibit VEGF/VPF-induced VP despite similar increases in systemic BP (Fig 5B) . These results support the notion that VEGF/VPFinduced VP is mediated by NO but is unaffected by NOindependent vasoconstriction.
Effect of Locally Administered L-NAME and Phenylephrine on VEGF/VPF-Induced Increase in VP
Neither L-NAME (0.001, 0.01, 0.1, and 1 mmol/L) nor phenylephrine (0.01 to 10 mol/L) alone increased VP (Fig 5C, D) . VP was reduced after administration of local VEGF/VPF with L-NAME (1 mmol/L) (Fig 5C) . Local administration of VEGF/ VPF with phenylephrine (1 mol/L) resulted in increased VP similar to that seen with VEGF/VPF alone (Fig 5D) .
Effects of NO Donors, Prostacyclin, and Prostacyclin Analogue Taprostene on VP
Since VEGF/VPF-induced VP was significantly attenuated by inhibitors of either NO synthase or cyclooxygenase, we then tested two NO donors and prostacyclin, a major metabolite of arachidonic acid by action of cyclooxygenase, for increased VP. NO donors, SNP (10, 50, 100, and 500 mol/L) and SNAP (10, 100, and 500 mol/L) alone each failed to increase VP (Fig 6A) . Similarly, prostacyclin (0.1 and 1 mol/L) and and inhibited VEGF/VPF-induced permeability. B, In vivo injection of phenylephrine (0.2 mg/kg) similarly increased blood pressure (91/69 to 140/92) but did not inhibit VEGF/VPF-induced increase in permeability. C, When VEGF/VPF was dissolved in saline containing 1 mmol/L L-NAME, VEGF/VPF-induced permeability was reduced. L-NAME alone (0.001 to 1 mmol/L) had no effect on permeability. D, When VEGF/VPF was dissolved in saline containing 1 mol/L phenylephrine, no reduction in permeability was observed; likewise, phenylephrine alone (0.01 to 10 mol/L) had no effect on vascular permeability. Representative photograph of two to three experiments. Scale barϭ10 mm. taprostene (0.01, 0.1, 1, and 10 mol/L) both failed, when administered alone, to increase VP (Fig 6B) . When SNP and taprostene were mixed and injected intradermally together, however, VP increased in a dose-dependent manner (Fig 6C) . (Histological examination of Giemsa-stained sections disclosed no evidence of mast-cell degranulation.) These results indicate that interaction between NO and prostaglandin (possibly prostacyclin) is required for increased VP.
Measurement of Nitric Oxide and Prostaglandin Metabolites in Cultured Microvascular Endothelial Cells
VEGF/VPF Stimulates NO Release From Microvascular Endothelial Cells
Because increased VP implies functional alteration in the microcirculation, we investigated the effects of VEGF/VPF on NO production in BMEC. Cross-reactivity of rhVEGF/VPF with BMEC was previously confirmed in our laboratory. 38 As shown in Fig 7A , VEGF/VPF (50 ng/mL) stimulated NO synthesis, with peak NO production 5 to 15 minutes after the addition of VEGF/VPF.
VEGF/VPF Stimulates Prostacyclin Release From BMEC
To assess the effects of VEGF/VPF on prostacyclin production, we measured 6-keto-PGF1␣, a stable metabolite of prostacyclin. VEGF/VPF (50 ng/mL) significantly stimulated 6-keto-PGF1␣ production in cultured BMEC in a timedependent manner (Fig 7B) .
Effect of Inhibitors on VEGF/VPF-Mediated Nitrite/Nitrate and 6-keto-PGF1␣ Production
We tested the effects of the NO synthase inhibitor L-NAME (100 mol/L), the cyclooxygenase inhibitor indomethacin (10 mol/L), and the tyrosine kinase inhibitor genistein (100 mol/L) on VEGF/VPF-mediated NO and 6-keto-PGF1␣ production. L-NAME significantly inhibited both NO and 6-keto-PGF1␣ production (Fig 8) . Indomethacin significantly inhibited 6-keto-PGF1␣ production but not NO release. Tyrosine kinase inhibitor genistein significantly attenuated both 6-keto-PGF1␣ and NO production significantly, consistent with the results of the Miles assay.
Role of Flt-1/VEGF-R1 Receptor Tyrosine Kinase in VEGF/VPF-Induced NO Synthesis
Because PlGF failed to increase VP in Miles assay, we tested whether PlGF stimulates NO synthesis in vitro. Consistent with the results of the Miles assay, PlGF (100 ng/mL) could not be shown to increase NO production from cultured BMEC (Fig 9) . 
Discussion
The present study demonstrates that (a) VEGF/VPFinduced VP is attenuated by NO synthase inhibitors, the cyclooxygenase inhibitor indomethacin, and tyrosine kinase inhibitor genistein; (b) PlGF, known to bind Flt-1/VEGF-R1 but not Flk-1/KDR/VEGF-R2, [32] [33] [34] did not increase VP; (c) other angiogenic cytokines including aFGF, bFGF, scatter factor (HGF), PDGF-BB, GM-CSF, and TGF-␤ all failed to increase VP; (d) VEGF/VPF stimulated NO and prostacyclin production in cultured microvascular endothelial cells, whereas PlGF failed to release NO; (e) neither NO donor (SNP or SNAP) nor prostacyclin administered alone increased VP, but combined administration of SNP and taprostene, a stable prostacyclin analogue, did lead to an increase in VP. These findings thus provide evidence that NO and prostacyclin production in microvascular endothelial cells mediate VEGF/ VPF-induced VP. Although histamine and PAF are known endogenous mediators of VP, our studies using receptor antagonists indicate that these molecules are not mediators of VEGF/VPF-induced increase in VP. Furthermore, histological examination revealed neither inflammatory cell infiltrates nor degranulated mast cells on Giemsa-stained sections (data not The increase in VP by combined administration of SNP and taprostene was not reversed by a histamine H1 receptor antagonist diphenhydramine (10 mg/kg) despite the fact that diphenhydramine completely inhibited histamine-induced permeability (Fig  1) . Representative photographs of two to three experiments each. Scale barϭ10 mm. shown) after intradermal injection of VEGF/VPF, consistent with previous data from Collins et al. 39 Our studies using genistein and herbimycin A confirmed essential role of receptor tyrosine kinase(s) in VEGF/VPFmediated VP. The demonstration that PlGF fails to augment VP confirms recent findings by Park et al 32 and implies that the Flt-1/VEGF-R1 tyrosine kinase receptor alone cannot mediate VEGF/VPF-induced VP [32] [33] [34] ; this effect instead appears to be mediated wholly or in part 40 by Flk-1/KDR/VEGF-R2. Furthermore, this feature is not shared by other growth factors that nevertheless stimulate angiogenesis in vivo.
VEGF/VPF stimulates transient accumulation of cytoplasmic calcium in cultured endothelial cells. 41 VEGF/VPFinduced increase in endothelial cytosolic Ca 2ϩ probably activates calcium-calmodulin-dependent enzymes such as endothelial constitutive NO synthase. In fact, Ku et al 24 previously showed that VEGF/VPF stimulates NO production in isolated canine coronary arteries. The present study extends these previous observations by demonstrating that VEGF/VPF also stimulates NO release from cells regulating VP at the microvascular level.
Previous studies have implicated NO as a factor regulating VP. 19 -21 Nguyen et al 21 demonstrated that substance P, a potent endothelium-dependent vasodilator, increases micro-VP through NO-dependent pathways. More recent findings suggested that NO-mediated alteration of VP may depend on its local concentration. 20 VEGF/VPF-induced VP appears dependent on not only NO but also prostaglandin production. It has been suggested that prostaglandins are involved in the regulation of both angiogenesis and VP. 25, 26 Yamamoto et al 25 recently reported that a stable prostacyclin analogue, SM-10902, accelerated wound healing in a murine model of diabetic skin ulcers. Fujii et al 26 have demonstrated that lipopolysaccharide-induced VP is attenuated by either an NO synthase inhibitor or indomethacin. These results collectively support the notion that prostaglandins produced from arachidonic acid by cycooxygenase can regulate VP.
Our data indicate that NO synthase inhibitor L-NAME inhibited not only nitrite production but also 6-keto PGF1␣ production from microvascular endothelial cells. This finding suggests a possible interaction between NO and prostaglandin. In this context, recent studies demonstrated that either endogenous or exogenous NO can stimulate prostaglandin production through cyclooxygenase activation. 36, 42 Thus increased production of prostacyclin in response to VEGF/VPF observed in our study might derive in part from NO stimulated by VEGF/VPF.
VP often precedes and/or accompanies angiogenesis, particularly tumor-associated angiogenesis. 5, 13, 43, 44 However, angiogenic growth factors other than VEGF/VPF failed to increase VP. This suggests that VEGF/VPF, in contrast to other angiogenic cytokines, directly enhances VP of an established mature vascular bed. Because most angiogenic cytokines have been shown to increase VEGF/VPF expression, [45] [46] [47] [48] [49] [50] VP associated with nascent vascular development stimulated by other angiogenic cytokines 51 may or may not be mediated by VEGF/VPF.
Endothelial cell-to-cell interaction and related adhesion molecules such as vascular endothelial cadherin, platelet endothelial cell adhesion molecule-1, and/or gap junction proteins have been implicated in the regulation of VP. 52 In contrast, Dvorak et al 13 and Kohn et al 53 found that vascular leakage could not be attributed to passage of molecules through interendothelial cell junctions or injured tumor endothelium Figure 8 . A, VEGF/VPF-induced (50 ng/mL) nitrite production as a marker of NO synthesis and B, VEGF/VPF-induced (50 ng/mL) 6-keto PGF1␣ production as a marker of prostacyclin synthesis. L-NAME (100 mol/L), an NO synthase inhibitor, and genistein (100 mol/L), a tyrosine kinase inhibitor, significantly inhibited VEGF/VPF-induced nitrite production, whereas indomethacin (10 mol/L) did not alter nitrite release. L-NAME, indomethacin, and genistein significantly inhibited VEGF/VPF-induced 6-keto PGF1␣ production (nϭ6 in each bar). *PϽ.05, **PϽ.01. Figure 9 . VEGF/VPF (100 ng/mL) significantly increased nitrite production, whereas PlGF (100 ng/mL), compared with controls (nontreated microvascular endothelial cells), did not (nϭ4 in each group). *PϽ.05, **PϽ.01.
but instead involved transendothelial transport through a novel cytoplasmic organelle that they termed the vesicular-vacuolar organelle. Others 54 have reported VEGF/VPF-induced ultrastructural features consistent with endothelial fenestration. The downstream details by which NO/prostacyclin-mediate VP may involve these routes remains to be fully elucidated.
